DE60021188T3 - Modifizierter humaner granulozyten-kolonie stimulierenderfaktor sowie verfahren zur herstellung desselben - Google Patents

Modifizierter humaner granulozyten-kolonie stimulierenderfaktor sowie verfahren zur herstellung desselben Download PDF

Info

Publication number
DE60021188T3
DE60021188T3 DE60021188T DE60021188T DE60021188T3 DE 60021188 T3 DE60021188 T3 DE 60021188T3 DE 60021188 T DE60021188 T DE 60021188T DE 60021188 T DE60021188 T DE 60021188T DE 60021188 T3 DE60021188 T3 DE 60021188T3
Authority
DE
Germany
Prior art keywords
csf
coli
modified
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60021188T
Other languages
German (de)
English (en)
Other versions
DE60021188D1 (de
DE60021188T2 (de
Inventor
Se Chang Kumcheon-gu KWON
Sung Youb Songpa-gu JUNG
Sung Min Bae
Gwan Sun Songpa-gu Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanmi Holdings Co Ltd
Original Assignee
Hanmi Pharmaceutical Co Ltd
Hanmi Pharmaceutical Industries Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36129291&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60021188(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Pharmaceutical Co Ltd, Hanmi Pharmaceutical Industries Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd
Publication of DE60021188D1 publication Critical patent/DE60021188D1/de
Publication of DE60021188T2 publication Critical patent/DE60021188T2/de
Application granted granted Critical
Publication of DE60021188T3 publication Critical patent/DE60021188T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/034—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60021188T 1999-07-08 2000-07-07 Modifizierter humaner granulozyten-kolonie stimulierenderfaktor sowie verfahren zur herstellung desselben Expired - Lifetime DE60021188T3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR9927418 1999-07-08
KR1019990027418A KR100356140B1 (ko) 1999-07-08 1999-07-08 인간 과립구 콜로니 자극인자 변이체 및 이의 생산 방법
PCT/KR2000/000733 WO2001004329A1 (en) 1999-07-08 2000-07-07 Modified human granulocyte-colony stimulating factor and process for producing same

Publications (3)

Publication Number Publication Date
DE60021188D1 DE60021188D1 (de) 2005-08-11
DE60021188T2 DE60021188T2 (de) 2006-04-27
DE60021188T3 true DE60021188T3 (de) 2010-04-01

Family

ID=36129291

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60021188T Expired - Lifetime DE60021188T3 (de) 1999-07-08 2000-07-07 Modifizierter humaner granulozyten-kolonie stimulierenderfaktor sowie verfahren zur herstellung desselben

Country Status (16)

Country Link
US (2) US20040224393A1 (enExample)
EP (1) EP1194575B2 (enExample)
JP (1) JP2003504069A (enExample)
KR (1) KR100356140B1 (enExample)
CN (1) CN1195859C (enExample)
AT (1) ATE299187T1 (enExample)
AU (1) AU757147C (enExample)
BR (2) BRPI0012265B8 (enExample)
CA (1) CA2378543C (enExample)
DE (1) DE60021188T3 (enExample)
DK (1) DK1194575T4 (enExample)
ES (1) ES2243275T5 (enExample)
NZ (1) NZ516476A (enExample)
PT (1) PT1194575E (enExample)
RU (1) RU2232772C2 (enExample)
WO (1) WO2001004329A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6831158B2 (en) 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
IL159524A0 (en) 2001-07-11 2004-06-01 Maxygen Holdings Ltd G-csf conjugates
US7611700B2 (en) * 2002-09-09 2009-11-03 Hanall Pharmaceuticals, Co., Ltd. Protease resistant modified interferon alpha polypeptides
US8338373B2 (en) * 2003-10-24 2012-12-25 Nora Therapeutics, Inc. Method for reducing the risk of spontaneous abortion in a human female subject
EP2198875A1 (en) 2003-10-24 2010-06-23 Nora, LLC A method for reducing the likelihood of preterm labour in a subject in need thereof
US20090226397A1 (en) 2003-10-24 2009-09-10 Nora Therapeutics, Inc. Compositions and methods for reducing the likelihood of implantation failure or miscarriage in recipients of artificial insemination
AU2006254543A1 (en) 2005-06-01 2006-12-07 Maxygen Holdings Ltd. PEGylated G-CSF polypeptides and methods of producing same
DE102005033250A1 (de) 2005-07-15 2007-01-18 Bioceuticals Arzneimittel Ag Verfahren zur Reinigung von G-CSF
EP2274325A4 (en) * 2008-05-13 2011-05-25 Nora Therapeutics Inc ANALOGUE OF HUMAN G-CSF AND METHOD OF MANUFACTURE AND APPLICATION THEREOF
JP5657698B2 (ja) 2010-01-19 2015-01-21 ハンミ サイエンス カンパニー リミテッドＨａｎｍｉ Ｓｃｉｅｎｃｅｃｏ．，Ｌｔｄ． 持続型顆粒球コロニー刺激因子結合体の液剤
TWI600759B (zh) 2010-04-02 2017-10-01 可娜公司 藉由抑制群落刺激因子３（ｃｓｆ３）之天然反義轉錄物以治療ｃｓｆ３相關疾病
KR101831300B1 (ko) 2010-10-29 2018-02-23 한미사이언스 주식회사 재조합 대장균으로부터 인간 과립구 콜로니 자극인자를 정제하는 방법
RU2467764C2 (ru) * 2011-01-12 2012-11-27 Государственное бюджетное образовательное учреждение дополнительного профессионального образования "Пензенский институт усовершенствования врачей" Министерства здравоохранения и социального развития Российской Федерации Способ лечения больных аутоиммунной хронической крапивницей с использованием внутривенного введения препарата "габриглобин"
KR101623906B1 (ko) 2014-07-23 2016-05-24 주식회사 이큐스앤자루 과립구 콜로니 자극인자 변이 단백질 또는 이의 트랜스페린 융합 단백질을 유효성분으로 포함하는 약학적 조성물
WO2016013725A1 (ko) * 2014-07-23 2016-01-28 주식회사 이큐스앤자루 과립구 콜로니 자극인자 변이 단백질 또는 이의 트랜스페린 융합 단백질을 유효성분으로 포함하는 약학적 조성물
KR102645064B1 (ko) 2017-02-03 2024-03-08 한미약품 주식회사 지속성이 증가된 생리활성 물질의 결합체 및 이의 용도
US11267858B2 (en) 2019-05-31 2022-03-08 Spectrum Pharmaceuticals, Inc. Methods of treatment using G-CSF protein complex
US11684655B2 (en) 2019-05-31 2023-06-27 Spectrum Pharmaceuticals, Inc. Methods of treating neutorpenia using G-CSF protein complex
KR102375269B1 (ko) * 2021-01-27 2022-03-17 한미약품 주식회사 단백질 액상 제제 및 이의 제조방법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPH01500483A (ja) * 1986-08-11 1989-02-23 シタス　コーポレイション Ｇ‐ｃｓｆ及びそのミューテインの発現
US5362853A (en) * 1986-12-23 1994-11-08 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
US5714581A (en) * 1986-12-23 1998-02-03 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
JPH02104598A (ja) 1988-04-12 1990-04-17 Kirin Amgen Inc ヒト顆粒球コロニー刺激因子ポリペプチド誘導体
NZ236819A (en) 1990-02-03 1993-07-27 Max Planck Gesellschaft Enzymatic cleavage of fusion proteins; fusion proteins; recombinant dna and pharmaceutical compositions
GB9107846D0 (en) 1990-04-30 1991-05-29 Ici Plc Polypeptides
EP0626448A3 (de) 1993-05-26 1998-01-14 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Verfahren zur Herstellung und Reinigung von alpha-Interferon
US6476198B1 (en) 1993-07-13 2002-11-05 The Scripps Research Institute Multispecific and multivalent antigen-binding polypeptide molecules
US5451660A (en) * 1993-12-13 1995-09-19 Genentech, Inc. Method for purifying polypeptides
EP0789776B1 (en) 1994-11-01 2001-06-13 Winfried Wels Nucleic acid transfer system
US6100070A (en) 1995-10-05 2000-08-08 G. D. Searle & Co. G-CSF receptor agonists
KR100316347B1 (ko) * 1998-09-15 2002-08-27 한미약품(주) 대장균엔테로톡신ⅱ신호펩티드의변형체와인체성장호르몬의융합단백질을발현하는재조합미생물및그를이용한인체성장호르몬의제조방법
NZ522847A (en) * 2000-05-16 2004-11-26 Bolder Biotechnology Inc Methods for refolding proteins containing free cysteine residues

Also Published As

Publication number Publication date
RU2232772C2 (ru) 2004-07-20
WO2001004329A1 (en) 2001-01-18
JP2003504069A (ja) 2003-02-04
KR100356140B1 (ko) 2002-10-19
ATE299187T1 (de) 2005-07-15
BRPI0012265B8 (pt) 2021-05-25
EP1194575A4 (en) 2002-10-24
DE60021188D1 (de) 2005-08-11
CN1195859C (zh) 2005-04-06
ES2243275T3 (es) 2005-12-01
KR20010009171A (ko) 2001-02-05
AU5710600A (en) 2001-01-30
CA2378543A1 (en) 2001-01-18
EP1194575A1 (en) 2002-04-10
BR0012265A (pt) 2002-03-12
ES2243275T5 (es) 2009-12-02
DK1194575T3 (da) 2005-10-17
AU757147C (en) 2005-03-03
EP1194575B1 (en) 2005-07-06
BRPI0012265B1 (pt) 2018-11-21
US20040224393A1 (en) 2004-11-11
PT1194575E (pt) 2005-10-31
NZ516476A (en) 2003-09-26
US7704709B2 (en) 2010-04-27
EP1194575B2 (en) 2009-08-26
DE60021188T2 (de) 2006-04-27
US20080064066A1 (en) 2008-03-13
DK1194575T4 (da) 2009-12-07
CN1360636A (zh) 2002-07-24
CA2378543C (en) 2010-05-18
AU757147B2 (en) 2003-02-06

Similar Documents

Publication Publication Date Title
DE60021188T3 (de) Modifizierter humaner granulozyten-kolonie stimulierenderfaktor sowie verfahren zur herstellung desselben
DE69233008T2 (de) Fusionierung von Peptiden und Proteinen mit Thioredoxin und thioredoxin-ähnlichen Molekülen
DE69929805T2 (de) Modifiziertes e.coli enterotoxin ii signalpeptid sowie ein mikroorganismus der ein fusionsprotein sowie ein heterologes protein exprimiert
DE69031997T2 (de) TNF(Tumor Necrosis Factor)-Inhibitor und Verfahren zur Herstellung
EP0513073B1 (de) VERFAHREN ZUR ENZYMATISCHEN SPALTUNG REKOMBINANTER PROTEINE UNTER VERWENDUNG VON IgA-PROTEASEN
DE69827507T2 (de) Trimerisierendes modul
DE69128362T2 (de) Zusammensetzungen und verfahren zur identifizierung von molekülen mit biologischer wirksamkeit
DE3789873T2 (de) Immunaffinitäts-reinigungssystem.
DD297188A5 (de) Gm-csf und il-3 umfassende fusionsproteine
DD210304A5 (de) Verfahren zur herstellung eines replikablen vektors
EP0750634A1 (en) Enhanced secretion of polypeptides
EP0324162A1 (de) Verfahren zur gentechnischen Herstellung von Antikörpern
DE3586972T2 (de) Gereinigtes interleukin-1.
EP0544292A2 (de) Verfahren zur Einschleusung von Nukleinsäuren in Zellen
DD219505A5 (de) Verfahren zur herstellung von schweine-wachstumshormonaehnlichen polypeptiden
DE69318909T2 (de) Verfahren zur Herstellung von menschlichem Wachstumshormon
DE3850878T2 (de) Elastase-inhibierungspolypeptide und verfahren zur herstellung durch genetische rekombination.
DE60209883T2 (de) Übersekretierte peptide, deren herstellung, und gleichzeitige verbesserung der sekretierten form eines oder mehrerer anderer polypeptide
DE60130100T2 (de) Expressions- und sekretionsvektor für menschliches interferon-alpha und verfahren zur herstellung von interferon-alpha durch anwendung desselben
DE69022901T2 (de) Streptokinase-Proteine, entsprechende Gene, entsprechende Plasmide und Verfahren zu deren Herstellung.
DE3751081T2 (de) [Leu 13] Motilin, dessen kodierende DNS-Moleküle und Verfahren zu dessen Herstellung.
DE68923496T2 (de) Verfahren zur Herstellung von motilinähnlichen Polypeptiden und seine Expression.
DE3687112T2 (de) Verfahren zur ausscheidung von genprodukten in das wachstumsmedium von gram-negativen bakterien.
DE3587205T2 (de) Verfahren zur herstellung eines proteins und dafuer zu verwendender vektor, rekombinante dns und transformierte zelle.
DE3485923T2 (de) Dna-gen, verfahren zu seiner herstellung und dieses gen enthaltendes plasmid.

Legal Events

Date Code Title Description
8363 Opposition against the patent
8328 Change in the person/name/address of the agent

Representative=s name: BOEHMERT & BOEHMERT, 28209 BREMEN

8366 Restricted maintained after opposition proceedings
8327 Change in the person/name/address of the patent owner

Owner name: HANMI HOLDINGS CO., LTD., SEOUL, KR

R082 Change of representative

Ref document number: 1194575

Country of ref document: EP

Representative=s name: BOEHMERT & BOEHMERT, DE